(VIANEWS) – Sarepta Therapeutics (SRPT), OGE Energy Corporation (OGE), Harmony Biosciences Holdings (HRMY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Sarepta Therapeutics (SRPT)
45.4% sales growth and 5.2% return on equity
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Earnings Per Share
As for profitability, Sarepta Therapeutics has a trailing twelve months EPS of $0.75.
PE Ratio
Sarepta Therapeutics has a trailing twelve months price to earnings ratio of 180.13. Meaning, the purchaser of the share is investing $180.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.2%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 65.2% and 187.2%, respectively.
Moving Average
Sarepta Therapeutics’s value is below its 50-day moving average of $145.18 and above its 200-day moving average of $123.45.
2. OGE Energy Corporation (OGE)
33.2% sales growth and 9.28% return on equity
OGE Energy Corp., together with its subsidiaries, operates as an energy and energy services provider that offers physical delivery and related services in the United States. It operates through Electric Company Operations and Natural Gas Midstream segments. The company generates, transmits, distributes, and sells electric energy. In addition, it provides retail electric service to approximately 889,000 customers, which covers a service area of approximately 30,000 square miles in Oklahoma and western Arkansas; and owns and operates coal-fired, natural gas-fired, wind-powered, and solar-powered generating assets. OGE Energy Corp. was founded in 1902 and is headquartered in Oklahoma City, Oklahoma.
Earnings Per Share
As for profitability, OGE Energy Corporation has a trailing twelve months EPS of $2.04.
PE Ratio
OGE Energy Corporation has a trailing twelve months price to earnings ratio of 19.27. Meaning, the purchaser of the share is investing $19.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 6.7% and 16.7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.5%, now sitting on 2.77B for the twelve trailing months.
Sales Growth
OGE Energy Corporation’s sales growth is negative 2.5% for the ongoing quarter and 33.2% for the next.
3. Harmony Biosciences Holdings (HRMY)
17.6% sales growth and 22.46% return on equity
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Earnings Per Share
As for profitability, Harmony Biosciences Holdings has a trailing twelve months EPS of $1.95.
PE Ratio
Harmony Biosciences Holdings has a trailing twelve months price to earnings ratio of 18.42. Meaning, the purchaser of the share is investing $18.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.46%.
Moving Average
Harmony Biosciences Holdings’s worth is way higher than its 50-day moving average of $32.28 and way higher than its 200-day moving average of $31.08.
4. CSG Systems International (CSGS)
13.8% sales growth and 19.69% return on equity
CSG Systems International, Inc., together with its subsidiaries, provides revenue management and digital monetization, customer experience, and payment solutions primarily to the communications industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers Advanced Convergent Platform, a private SaaS platform; and related solutions, including service technician management, analytics, electronic bill presentment, etc. The company also provides a public SaaS-based revenue management and payments platform. In addition, it offers managed services; and professional services to implement, configure, and maintain its solutions, as well as licenses various solutions, such as mediation, partner management, rating, and charging. Further, the company provides operational services, including infrastructure management comprised of hardware, application, and environmental management; application configuration management, such as configuration development, release, and deployment; and business operations management, which includes event processing, revenue management, and settlement. It serves retail, financial services, healthcare, insurance, and government entities. The company was incorporated in 1994 and is headquartered in Englewood, Colorado.
Earnings Per Share
As for profitability, CSG Systems International has a trailing twelve months EPS of $2.22.
PE Ratio
CSG Systems International has a trailing twelve months price to earnings ratio of 21.86. Meaning, the purchaser of the share is investing $21.86 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.69%.
Volume
Today’s last reported volume for CSG Systems International is 170744 which is 22.11% below its average volume of 219215.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Sep 13, 2024, the estimated forward annual dividend rate is 1.2 and the estimated forward annual dividend yield is 2.47%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 15.2% and 23.9%, respectively.
5. Allegheny Technologies Incorporated (ATI)
12.5% sales growth and 28.61% return on equity
Allegheny Technologies Incorporated manufactures and sells specialty materials and components worldwide. The company operates in two segments, High Performance Materials & Components and Advanced Alloys & Solutions. The company produces high performance materials, including titanium and titanium-based alloys; nickel-and cobalt-based alloys and superalloys; zirconium and related alloys, such as hafnium and niobium; powder alloys; and other specialty materials in long product forms of ingots, billets, bars, rods, wires, and shapes and rectangles, as well as seamless tubes, plus precision forgings, castings, components, and machined parts to the aerospace and defense, medical, oil and gas, and electrical energy markets. It also provides stainless steel, nickel-based alloys, specialty alloys, and titanium and titanium-based alloys in various product forms, including plate, sheet, and precision rolled strip products to various markets, such as chemical and hydrocarbon processing,. Allegheny Technologies Incorporated was founded in 1960 and is based in Pittsburgh, Pennsylvania.
Earnings Per Share
As for profitability, Allegheny Technologies Incorporated has a trailing twelve months EPS of $2.65.
PE Ratio
Allegheny Technologies Incorporated has a trailing twelve months price to earnings ratio of 25.35. Meaning, the purchaser of the share is investing $25.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.61%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.7%, now sitting on 4.23B for the twelve trailing months.
Moving Average
Allegheny Technologies Incorporated’s value is way higher than its 50-day moving average of $60.10 and way higher than its 200-day moving average of $51.47.
6. Vertex (VERX)
12.4% sales growth and 8.62% return on equity
Vertex, Inc. provides tax technology solutions for corporations in retail, leasing, communication, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also offers implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. The company was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Vertex has a trailing twelve months EPS of $0.13.
PE Ratio
Vertex has a trailing twelve months price to earnings ratio of 283.62. Meaning, the purchaser of the share is investing $283.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.62%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.3%, now sitting on 617.83M for the twelve trailing months.
Volume
Today’s last reported volume for Vertex is 376564 which is 62.77% below its average volume of 1011460.
Previous days news about Vertex(VERX)
- 3 reasons why growth investors shouldn't overlook vertex (verx). According to Zacks on Monday, 2 September, "Right now, year-over-year cash flow growth for Vertex is 21.3%, which is higher than many of its peers. ", "While the historical EPS growth rate for Vertex is 16.7%, investors should actually focus on the projected growth. "
7. Packaging Corporation of America (PKG)
7.5% sales growth and 18.01% return on equity
Packaging Corporation of America manufactures and sells containerboard and corrugated packaging products in the United States. The company operates through Packaging and Paper segments. The Packaging segment offers various containerboard and corrugated packaging products, such as conventional shipping containers used to protect and transport manufactured goods; multi-color boxes and displays that help to merchandise the packaged product in retail locations; and honeycomb protective packaging products, as well as packaging for meat, fresh fruit and vegetables, processed food, beverages, and other industrial and consumer products. This segment sells its corrugated products through a direct sales and marketing organization, independent brokers, and distribution partners. The Paper segment manufactures and sells commodity and specialty papers, as well as communication papers, including cut-size office papers, and printing and converting papers. This segment sells white papers through its sales and marketing organization. Packaging Corporation of America was founded in 1867 and is headquartered in Lake Forest, Illinois.
Earnings Per Share
As for profitability, Packaging Corporation of America has a trailing twelve months EPS of $7.97.
PE Ratio
Packaging Corporation of America has a trailing twelve months price to earnings ratio of 25.71. Meaning, the purchaser of the share is investing $25.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.01%.
Sales Growth
Packaging Corporation of America’s sales growth for the next quarter is 7.5%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.3%, now sitting on 7.93B for the twelve trailing months.
Moving Average
Packaging Corporation of America’s worth is above its 50-day moving average of $191.20 and way higher than its 200-day moving average of $177.89.
8. DexCom (DXCM)
6.2% sales growth and 29.41% return on equity
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $1.3.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 104.72. Meaning, the purchaser of the share is investing $104.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.41%.
